Navigation Links
Discovery may help fight late-stage ovarian cancer
Date:11/16/2011

A potential breakthrough in treating late-stage ovarian cancer has come from University of Guelph researchers who have discovered a peptide that shrinks advanced tumours and improves survival rates for this deadly but often undetected disease.

"We're extremely excited about this," said Jim Petrik, a professor in U of G's Department of Biomedical Sciences who conducted the research with PhD student Nicole Campbell. "It has the potential, particularly in ovarian cancer, to have a significant impact."

Their findings will appear in Molecular Cancer Therapeutics, published by the American Association for Cancer Research.

Ovarian cancer is the most lethal gynecological cancer. Its symptoms, which include nausea, bloating and abdominal pain, are vague and can be attributed to a number of ailments.

Often the disease remains undetected until it's well advanced, when the odds of survival are poor. "It's called the silent killer because it really does sneak up on you," Petrik said.

He and Campbell discovered that ABT-898, a peptide derived from the thrombospondin molecule, shrinks established late-stage tumours in mouse models of ovarian cancer. In addition to regressing tumours, ABT-898 essentially prunes dysfunctional blood vessels in the tumour while leaving healthy vessels intact.

Petrik explains that chemotherapy treatment relies on blood vessels to transport tumour-fighting drugs. But abnormal blood vessels inside tumours make drug delivery inefficient.

"This new treatment enhances the ability to deliver chemotherapy drugs inside of the tumour where they need to go. So in combination with chemotherapy, it has fantastic potential."

Besides shrinking tumours, ABT-898 improves survival rates because cancer cells do not have time to adapt to the treatment.

"This is crucial. Women tend to succumb to ovarian cancer because the inefficient delivery of chemotherapy drugs allows the cells to build up resistance and they no longer respond to treatment," Petrik said.

More efficient drug delivery also means doctors can administer lower amounts, alleviating many of the side effects of chemotherapy. As well, said Petrik, "this is a naturally occurring protein that we are exploiting; we are not making anything synthetic."

He hopes the research will lead to human trials and, ultimately, to the development of targeted cancer therapies.

Petrik has studied ovarian cancer for more than a decade, especially regulation of growth factors and formation of blood vessels in the ovary. A U of G faculty member since 2001, he teaches physiology and anatomy at the Ontario Veterinary College.

This latest discovery was possible because Petrik's laboratory had developed a model in which cancer cells are injected directly into healthy mouse ovaries. Ovarian cancer spontaneously occurs in about two months, allowing U of G researchers to follow tumour progression.

Most researchers rely on artificially cultured clumps of cells and immunocompromised mice that poorly mimic disease progression in normal animals.

"It provides us with a tool to ask questions like this and look at interventions such as this in a way that is far more relevant to the human disease," Petrik said.


'/>"/>

Contact: Jim Petrik
jpetrik@ovc.uoguelph.ca
519-824-4120 x54921
University of Guelph
Source:Eurekalert

Related medicine news :

1. Lab-made skin cells will aid transplantation, cancer, drug discovery research
2. Will my breast cancer spread? Discovery may predict probability of metastasis
3. Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment
4. Penn receives $12.5 million from NIH to speed discovery to patient care
5. A*STAR scientists make headway for cancer treatment and cancer prevention with landmark discovery
6. New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery
7. Sweet insight: Discovery could speed drug development
8. URMC and Temple announce drug discovery partnership
9. Stanford discovery may eliminate potentially lethal side effect of stem cell therapy
10. Brain tumor discovery could lead to new treatment
11. Discovery of a new mechanism of gene control that is associated with cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
(Date:3/24/2017)... , ... March 24, 2017 , ... Digital Scientists, a ... to announce the opening of a Greenville, South Carolina location. The lab ... progress in Greenville. , “We’ve been working with South Carolina clients for years from ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance ... to families and business owners across eastern Michigan, is connecting with the Oxford/Orion ... with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure homeless, ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, Cassie ... Litigation seminar in Chicago, Illinois. She will present on: , Filing Benefit ... under ERISA involve claims for long-term disability benefits. This session will address ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of ... Frederick, MD. Judy says, “I am passionate about sharing Reiki as a holistic, ... difficult and challenging time.” , A Certified Medical Reiki™ Master trained by Raven ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:3/24/2017)... 2017  HealthMine surveys with 9,250 insured consumers fielded ... plan members want help from their plans in five ... their health, 2) help closing gaps in care, 3) ... and 5) relevant, real-time guidance. Meeting these needs is ... A Reason to Stay Engaged ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... efforts to develop sutezolid as effective response to infectious ... TB Alliance and the Medicines Patent Pool (MPP) announced ... an antibiotic drug candidate which demonstrated encouraging results in ... sutezolid in combination with other TB drugs and follows ...
Breaking Medicine Technology: